Nova Eye Medical Ltd Reports Strong Sales Growth and Positive EBITDA
Key points
- FY26 total sales of US$23.7 million, up 26% year-over-year
- Sales excluding China reached US$22.7 million, up 29% year-over-year
- Achieved positive EBITDA of US$0.14 million in H2FY26
- Group cash outflow from operations reduced to A$0.2 million for the quarter
- FY27 sales, excluding China, expected to be between US$26 million and US$31 million
Full summary
Nova Eye Medical Ltd reported total sales of US$23.7 million for the year ended 30 June 2026, marking a 26% increase year-over-year. Sales excluding China reached US$22.7 million, up 29% year-over-year. The company achieved a positive EBITDA of US$0.14 million in the second half of FY26, ahead of guidance. Group cash outflow from operations reduced to A$0.2 million for the quarter. The company expects sales, excluding China, to be between US$26 million and US$31 million in FY27, with positive EBITDA expected.
Guidance
FY27 sales, excluding China, expected to be between US$26 million and US$31 million
Outlook
Nova Eye Medical Ltd expects continued growth in FY27, with positive EBITDA anticipated. The company's cash position and existing debt facilities are expected to support these growth targets.
Summary generated by a large language model. Please interpret with care.